CITADEL ADVISORS LLC

Position in ATAI — AtaiBeckley Inc.

CIK 1423053 MIAMI, FL

Back to ATAI Full portfolio

Position in ATAI

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$11,145,564

+$10,538,851 QoQ

Shares Held

2,114,908

+1134.0% QoQ

Ownership

0.570%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#13

of 239 holders

Holding Since

Mar 2026

2 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in ATAI Over Time

Shares Held

Position Value (USD)

Derivatives in ATAI

reported options exposure · as of Jun 30, 2026

CallValue

$1,180,480

CallShares

224,000

PutValue

$951,762

PutShares

180,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. ATAI ranks #94 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ONC	BeOne Medicines Ltd.	1,425,517	$406,229,578
2	BBIO	BridgeBio Pharma, Inc.	3,760,028	$280,046,885
3	INSM	INSMED Inc	2,556,973	$272,624,460
4	MDGL	Madrigal Pharmaceuticals, Inc.	507,233	$272,358,759
5	VRTX	Vertex Pharmaceuticals Inc / Ma	510,430	$253,545,893
6	JAZZ	Jazz Pharmaceuticals plc	1,006,676	$242,578,715
7	MANE	Veradermics, Inc	1,877,775	$230,853,658
8	ROIV	Roivant Sciences Ltd.	5,576,261	$197,343,876

All Filings in ATAI

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$951,762	180,600	+70.2%	Put	Defined	2026-08-14
2026-06-30	$11,145,564	2,114,908	+1134.0%	Shares	Defined	2026-08-14
2026-06-30	$1,180,480	224,000	-14.2%	Call	Defined	2026-08-14
2026-03-31	$375,594	106,100	—	Put	Defined	2026-05-15
2026-03-31	$924,648	261,200	—	Call	Defined	2026-05-15
2026-03-31	$606,713	171,388	—	Shares	Defined	2026-05-15
No filing history on record for this holder in this stock.